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Antitumour agents in current use tend to be cytotoxic but non-
selective, indiscriminately killing both normal and tumour cells,
and resulting in toxic side-effects and development of resistance.
An alternative and perhaps more desirable approach is to selec-
tively convert cancer cells to a differentiated, non-proliferating
phenotype. This strategy has the potential to be tissue-specific and
to avoid the genotoxic side-effects of current anticancer drugs
(Marks et al, 1994; Rifkind et al, 1996). A few differentiating
agents of relatively low potency have reached clinical trial (Beere
and Hickman, 1993), with retinoic acid showing promise for some
lymphoid neoplasms. However, the success of this approach has
not been fully explored due to the low potency and lack of selec-
tivity for tumour cells of drugs in this class. Expression of many
genes in a particular cell type are also affected by these non-selec-
tive agents, confounding mechanistic studies of cell arrest.
Hexamethylene bisacetamide (HMBA) is one such differenti-
ating agent that has low potency in various murine and human
leukaemic and solid tumour cell lines (Marks et al, 1994; Rifkind et
al, 1996). Nevertheless, it has produced remissions in patients with
myelodysplastic syndrome and acute myoblastic leukaemia
(Andreef et al, 1992), although it suffers from rapid degradation
(deacylation) in vivo and side-effects such as acidosis and neuro-
toxicity (Marks et al, 1994). The lack of tumour selectivity has been
noted (Rowinsky et al, 1992) and combination with other agents
has been suggested as a way of enhancing its activity. In murine
erythroleukaemic cells, HMBA induces arrest in G1, translocation
of protein kinase C (PKC) from the cytosol to the membrane,
decrease in c-myb, c-myc and p53 proteins and increase in c-fos
mRNA (Marks et al, 1994; Rifkind et al, 1996). A transient
increase in hypophosphorylated retinoblastoma protein pRB was
found 12 h after treatment, followed by enhanced production of the
hyperphosphorylated form ppRB, p107 mRNA, and protein during
the next 2–3 days (Kiyokawa et al, 1994; Marks et al, 1994).
Binding of the key cell cycle-regulating transcription factor E2F to
its DNA motif was inhibited by HMBA within 8 h (Richon and
Ventaperez, 1996). HMBA also inhibits poly(ADP)ribosylation
(Thyberg et al, 1995) and expression of cyclin A (Nakamura et al,
1995), and causes hypomethylation of DNA (Palliti et al, 1993).
Recently, a number of HMBA-related agents that contain one or
more hydroxamate groups have been examined as differentiating
agents (Breslow et al, 1991; Schroy et al, 1994; Richon et al, 1996;
Parsons et al, 1997). This behaviour is different from that known
for other hydroxamates that inhibit matrix metalloproteases and
also show promise as anti-tumour agents (Rasmussen and
McCann, 1997). Azelaic bishydroxamate (ABHA) is not a
metalloprotease inhibitor but induces differentiation in murine
erythroleukaemic cell lines, human promyelocytic cells (HL-60),
and human colon carcinoma cells (Breslow et al, 1991; Schroy et
al, 1994). This compound and certain analogues are up to 100-fold
more active than HMBA in vitro and several have been found to
inhibit histone deacetylase (Richon et al, 1998) and induce apop-
tosis (McBain et al, 1997).
Upon comparing the in vitro effects of azelaic acid, HMBA and
ABHA, we found that ABHA was selectively toxic for some
human tumour cell lines and SV40-transformed melanocytes
compared with normal cells (Parsons et al, 1997). After treatment
with ABHA, dendritic morphology was the only detected indicator
of increased differentiation, markers for the pigmentation pathway
being unchanged or down-regulated. ABHA resembled a more
potent form of butyrate in some transcriptional activities, raising
the possibility that it regulates gene expression via hyperacety-
lation of histones. Acetylation of the N-terminal lysine side-chains
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in histone H4 regulates gene expression by blocking access of
transcription and other factors to DNA, the level of histone
acetylation being determined by histone acetyl-transferases and
deacetylases (Wolffe and Pruss, 1996). Butyrate and the potent
differentiating agents trichostatin A (TSA) and trapoxin cause
hyperacetylation by inhibiting histone deacetylase (Kijima et al,
1993; Yoshida et al, 1995).
We now show that ABHA and a related hydroxamate are active
in vivo against xenografts of a drug-resistant human melanoma
cell line as well as being active in vitro against most of the human
tumour cell lines tested. We also demonstrate that the action of
ABHA requires macromolecular synthesis and phosphatase
activity, and causes hyperacetylation of histone H4, in sensitive
and resistant cells.
MATERIALS AND METHODS
Chemistry
Azelaic-1-hydroxamate-9-anilide (AAHA)
Azelaic acid (20 g, 106 mmol) was treated with thionyl chloride
(25 ml) and the mixture refluxed for 30 min. Solvent was removed
in-vacuo and to the residue was added drop-wise a solution
containing aniline (10.65 mL, 117 mmol), N-methylmorpholine
(12.85 ml, 117 mmol) and dichloromethane (100 ml). After addition
was complete, the mixture was allowed to stir at room temperature
for 20 min before evaporating the dichloromethane in vacuo. The
residue was taken up into 200 ml of 5% sodium hydroxide and
extracted with 3 ´ 100 ml aliquots of ethyl acetate. The basic layer
was separated, acidified with 6 M hydrochloric acid (HCl) and
extracted with 3 ´ 100 ml aliquots of ethyl acetate. The organic
extracts were combined, dried (magnesium sulphate (MgSO4)) and
concentrated to yield the anilide (15.6 g, 56%). To a sample of the
crude anilide (200 mg, 0.76 mmol) in dry tetrahydrofuran (20 mL)
was added N-methylmorpholine (0.092 ml, 0.85 mmol) and
isobutylchloroformate (0.110 mL, 0.85 mmol). The mixture was
stirred for 10 min before a solution containing hydroxylamine
hydrochloride (58.2 mg, 0.85 mmol), ethanol (10 ml) and 5%
sodium hydroxide (0.94 ml) was added. After a further 10 min,
the solvent was removed in-vacuo and the residue taken up into
100 ml of 1 M HCI and extracted with 3 ´ 30 ml aliquots of
dichloromethane. The organic extracts were combined, dried
(MgSO4) and concentrated to yield 130 mg of crude material which
was purified by reverse phase high performance liquid chromatog-
raphy (HPLC) to give 15 mg (7.1%) of the desired bis-hydroxamic
acid: 1H NMR (300 MHz, DMSO-d 6); d 1.29 (6H, m), 1.48 (2H,
m), 1.58 (2H, m), 1.94 (2H, t), 2.28 (2H, t), 7.00 (1H, t), 7.26 (2H, t),
7.58 (2H, d), 8.65 (1H, br.s), 9.85 (1H, s), 10.3 (1H, br.s); 13C NMR
(75.6 MHz, DMSO-d 6); d 25.27,28.65, 28.70,  28.75, 32.43, 36.58,
119.19, 123.08, 128.04, 139.51, 169.27, 171.41.
Cell culture
Cell lines (Maynard and Parsons, 1986) were grown in RPMI-1640
culture medium supplemented with 5% heat inactivated fetal calf
serum (FCS), at 37°C in a humidified atmosphere containing 5%
carbon dioxide air. Human melanocytes were maintained in culture
media supplemented with 10% FCS, 10 ng ml–1 TPA (12-O-
tetradecanoylphorbol-13-acetate) and 6 ng ml cholera toxin. All
cell lines were tested monthly for Mycoplasma using a Hoescht
staining technique (Chen, 1977). Cell survival was determined on
cells treated in microtitre plates for 24 h and allowed to recover for
5 days before determination of incorporation of 3H-thymidine
(Maynard and Parsons, 1986), or reduction of MTT (3-(4,5-
dimethylthiazal-2-yl)-2,5-diphenyltetrazolium bromide (Mossman,
1983). These methods give similar results to clonal-type assays or
counting cell number (Parsons et al, 1991, 1997).
Cell fusion
The double marker HeLa cell line, HHM, was obtained by selection
with 100 mM 2-amino-6-mercaptopurine to generate HPRT-clones,
followed by transfection with the plasmid p294MetM3 (Parsons et
al, 1997) that expresses hygromycin resistance. HHM cells were
resistant to 100 mg ml–1 hygromycin B and sensitive to HAT (5 mM
hypoxanthine, 20 mM aminopterin, 0.8 mM thymidine).
A2058 or NFF cells were co-cultivated with HHM at a ratio of
10:1 respectively until confluent, in RPMI-1640–10% FCS. The cell
monolayer was washed twice with RPMI-1640 serum-free medium
and exposed to 500 ml of RPMI-1640 serum-free medium per 50%
v/v PEG 1500 for 30 s. Medium was aspirated and cells maintained
for a further 60 s. The monolayer was washed stringently (5 ´) with
RPMI-1640 serum-free medium and incubated for a further 2 h in 2
ml RPMI-1640 serum-free medium. This was replaced with RPMI-
1640 medium supplemented with 10% FCS. Double selection with
HAT and 100 mg ml–1 hygromycin B was commenced 24 h post-
fusion. Colonies were picked and propagated.
AB
C D
E F
G H
Figure 1 Effect on cell morphology (Geimsa stain) of 24-h treatment with
100 mg ml–1 ABHA. Left panels, untreated. Right panels, treated. (A,B)
MM96L melanoma; (C, D) melanocytes; (E, F) HeLa; (G, H) NFF fibroblasts1254 L Qiu et al
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Mouse experiments
Xenografts of melanoma MM96L were produced by subcutaneous
(s.c.) injection of 2 ´ 106 cells per site on the flanks of nude
(nu/nu) mice as previously described (Parsons et al, 1991). After 1
week to allow the cells to become established as tumours, the mice
were treated once daily (5 days per week) intraperitoneally (i.p.)
with 4 mg ABHA in 0.5 ml phosphate-buffered saline (PBS), 5 mg
AAHA in 50 ml 80% dimethyl sulphoxide (DMSO) or 25 mg TSA
in 0.2 ml PBS. The animals were euthanized when a tumour
reached 1 cm diameter.
Histone acetylation
Histones were extracted in HCl and analysed directly on Triton–urea
15% polyacrylamide gels with Coomassie blue (Saito et al, 1991).
Gels were scanned with a laser densitometer (Molecular Dynamics,
Sunnyvale, CA, USA) and quantitated with ImageQuant software.
RESULTS
Cell morphology and survival
Treatment of normal cells (melanocytes, fibroblasts) with ABHA
for 24 h led to some enlargement of the cytoplasm but no major
morphological changes (Figure 1). Tumour cells (MM96L, HeLa),
became highly dendritic following similar treatment, with the
MM96L melanoma cells resembling the morphology of normal
melanocytes (Figure 1C, D). Some membrane damage was evident
with vesicles forming from the plasma membrane in some cells, as
well as cells undergoing apoptosis.
Simultaneous treatment of cells with ABHA and a range of
inhibitors demonstrated that formation of dendritic morphology
was dependent on protein and RNA synthesis, and to a lesser
extent, phosphatase activity (Figure 2).
As found previously in cell growth assays (Parsons et al, 1997),
incorporation of 3-H-thymidine 5 days after a 24-h treatment
confirmed that the human melanoma cell line MM96L and the
cervical carcinoma cell line HeLa were sensitive to killing by
ABHA compared with fibroblasts (NFF) (Figure 3A). The
melanoma cell line MM229 had intermediate sensitivity. AAHA,
the anilide derivative of ABHA, showed similar discrimination
and was more potent (Figure 3B). TSA (Figure 3C) was approxi-
mately 100-fold more potent than the two previous drugs, but was
somewhat less selective for killing fibroblasts. A survey of other
human cell types (Table 1 and Figure 8A) showed that only two
tumour cell lines (MM229 and A2058) of 11 human tumour and
transformed cell lines were as resistant to ABHA and AAHA as
proliferating normal cells (NFF and NM).
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Figure 2 Formation of dendritic HeLa cells during a 24-h treatment with 
100 mg ml–1 ABHA was inhibited by co-treatment with 10 mg ml–1
cycloheximide (n n), 2 mg ml–1 actinomycin D (n) or 1 mM sodium vanadate
(l l). Addition at 0 h represents 24-h treatment with inhibitors, giving
maximum inhibition of dendrite formation. Points are means of triplicates
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Figure 3 Selective toxicity of ABHA (A), AAHA (B) and TSA (C) in human cells. s, NFF; n n, MM96L; •, MM229; u u, HeLa, Points are mean and s.d. (n = 4)Anti-tumour activity of differentiating agents 1255
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Inhibition of the growth of human melanoma
xenografts in nude mice
Preliminary experiments showed that daily i.p. doses of ABHA up
to 8 mg had no discernible toxicity to BALB/c mice. ABHA
administered at 4 mg per day, commencing 7 days after implanta-
tion of tumour cells, led to significant inhibition of tumour growth
(Figure 4A). AAHA was also effective, whereas TSA, applied daily
at a dose calculated from cell survival curves to be approximately
fivefold the in vitro toxicity of ABHA, was inactive (Figure 4B).
Incubation of the drugs with near-confluent cultures of NFF or
MM96L cells for up to 3 days, followed by bioassay of the
remaining toxicity by transfer of the medium to fresh cultures of
MM96L cells, revealed that TSA was slowly inactivated (Figure 5).
No weight loss or other evidence of toxicity was observed in the
treated mice. The small tumours remaining on the treated mice
were re-cultured and found to retain the same in vitro sensitivity to
ABHA as MM96L cells from the untreated tumours.
Hyperacetylation of histones
Analysis of histones extracted from MM96L or NFF cells after
24 h treatment with ABHA showed a distinct laddering of the H4
region (Figure 6), indicative of increasing levels of acetylation of
this histone. Similar results were obtained using 10 mg ml–1
AAHA, 100 nM TSA or 5 mM butyrate (not shown). The temporal
response, measured from laser densitometer traces (Figure 7A),
showed that acetylation commenced within 2 h of treatment, the
tetra-acetylated form becoming prominent by 24 h. In repeated
experiments, however, no significant difference could be found
between MM96L and NFF in the amount of tetra-acetylated form
induced by ABHA (Table 2).
Since it was possible that ABHA selectivity for cell killing may
have arisen from decreased rate of removal of acetyl groups from
H4 histone after removal of drug, cells were analysed at different
times during recovery from a 2-h treatment with ABHA. The
results, however, revealed that H4 acetylation in the drug-resistant
NFF cells decayed more slowly than in the sensitive MM96L cells
(Figure 7B), thus ruling out delayed recovery from acetylation as
the cause of sensitivity.
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Figure 4 Inhibition of the growth of the human melanoma cell line MM96L
as xenografts in nude mice. (A) ABHA (4 mg per day). (B) AAHA (5 mg per
day) and TSA (25 mg per day). Points are mean and s.d. (n = 7–11 per group)
Table 1 Toxicity of histone deacetylase inhibitors in human cells
D37
a
Cell Cell type TSA ABHA AAHA
(ng ml–1)( mg ml–1)( mg ml–1)
Normal
NFF Fibroblasts 50 > 300 > 100
NM Melanocytes 170 196 > 100
Tumour
MM96L Melanoma 10 14 8.0
MM229 Melanoma 413 179 26
MM418c1 Melanoma 38 16 6
HT 144 Melanoma 120 72 39
HeLa Cervical carcinoma 50 56 30
A549 Lung carcinoma 39 28 8.7
LIM 1215 Colon carcinoma 30 26 10
C180–13S Ovarian cancer 10 10 8.0
JAM Ovarian cancer – 11 –
Transformed
293 Kidney – 1 86
aDose required to lower survival to 37% of control.
Table 2 Acetylation of histone H4 during 24-h treatment with differentiating
agents
Tetra-acetyl-H4 (% total H4)a
Cell 0 ABHA Butyrate
(100 mg ml–1)( 5 m M)
MM96L 0 28 ± 4.3b 18
MM229 0 23 13
HeLa 0 32 12
NFF 0 20 ± 1.6b 22
Melanocyte 0 13 NT
aHistones separated on Triton–urea gels were stained with Coomassie blue
and quantitated with a laser densitometer. bMean and s.d. of 2–3
experiments.
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Figure 5 Loss of potency of TSA during incubation with confluent MM96L
cells. At each time, aliquots of culture medium were bioassayed for toxicity
by 24-h treatment of separate cultures of MM96L cells. s, TSA (100 ng ml–1);
n, ABHA (100 mg ml–1). Points are mean and s.d. (n = 4)1256 L Qiu et al
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Sensitivity of cell hybrids to ABHA
Fusion of ABHA-sensitive (HHM) with resistant cells (NFF,
A2058) followed by double selection with HAT and hygromycin
to remove homokaryons produced stable, proliferating clones.
These were identified as hybrids by DNA flow cytometry, which
revealed the G1 DNA content to be the sum of the G1 DNA of the
fusion partners. The presence of the NFF or A2058 genomes was
confirmed independently by increased resistance of the hybrids
to the methylating agent N-methyl-N´-nitro-N-nitrosoguanidine
compared with HeLa, which is sensitive to DNA methylating
agents (Maynard and Parsons, 1986). No clones were obtained
from fusions carried out with HeLa cells that lacked either of the
selection markers. Clones of both NFF/HHM and A2058/HHM
cell hybrids displayed distinct sensitivity to ABHA and AAHA,
compared with the resistant partner cell line (Figure 8).
DISCUSSION
A large number of hydroxamate-containing compounds are now
known to possess anti-tumour properties. Most such compounds
non-selectively inhibit matrix metalloproteases, which are associ-
ated with growth and spread of malignant tumours in models of
metastasis, angiogenesis and tumour progression. In contrast,
ABHA does not inhibit metalloproteases even at mM concentra-
tions (unpublished), yet has anti-tumour activity. A wide variety of
tumour cell types and SV40-transformed melanocytes (Parsons et
al, 1997) are sensitive to ABHA and derivatives (Table 1).
Selectivity appears to be a novel property of this drug class, since
normal cells and only two melanoma cell lines (MM229, A2058)
were resistant to the agents.
The morphological changes illustrated in Figure 1 occur within
24 h of treatment with ABHA and are attributed to some form of
differentiation or ‘redifferentiation’ and partial reversion to a
normal phenotype. While some of the melanoma cells have
enhanced dendritic, melanocytic morphology after treatment, there
is also some accompanying apoptosis, and the tumour cells ulti-
mately die. Protein and RNA synthesis de novo was required for
this phenotype reversion, as found previously for TSA-induced
differentiation of HeLa cells (Hoshikawa et al, 1994), suggesting
that ABHA is not acting solely as an inhibitor of cellular functions
but also induces the transcription of genes necessary for differenti-
ation and possibly cell death.
Xenografts of the melanoma MM96L cells were significantly
inhibited by daily treatments with ABHA, the first drug of any
kind to show significant activity against this cell line. Although
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Figure 6 Separation of histones on a Triton–urea polyacrylamide gel
showing induction of histone H4 acetylation in cells treated for 24 h with 
100 mg ml–1 of ABHA (+)
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Figure 7 (A) Densitometer profiles of histone gels showing the temporal
increase in H4 acetylation in sensitive (MM96L) and resistant (NFF) cells. 
(B) Temporal response for loss of acetylated H4 after a 2-h treatment with
10 mg ml–1 ABHA. n, NFF; n n, MM96LAnti-tumour activity of differentiating agents 1257
British Journal of Cancer (1999) 80(8), 1252–1258 © 1999 Cancer Research Campaign 
this is a relatively high dose (200 mg kg–1), other differentiating
agents such as butyrate have been used safely at similar levels to
treat children with sickle cell anaemia (Perrine et al, 1994).
Established from a metastasis, having a mutator phenotype (Must
et al, 1996) and resistant to current anticancer agents in vitro and
in vivo (Maynard and Parsons, 1986), MM96L cells represent a
rigorous, but probably realistic, human model for testing new
agents. MM96L cells cultured from the small tumours that
survived treatment of the mice by ABHA were still sensitive to
ABHA. The inability of such a tumour cell line to develop resis-
tance to ABHA is notable, and suggests that even higher doses of
ABHA could be given, since there were no overt signs of toxicity
or side-effects in the mice. AAHA, administered in DMSO
because of poor solubility in aqueous PBS, had even better
activity. Metabolic inactivation of TSA, detected here for the first
time, is expected to be more marked in vivo due to exposure to the
liver and kidney, and is a possible explanation for its complete lack
of activity against human melanoma xenografts. Resistance of
cultured fibroblasts to TSA is unlikely to be due to metabolism of
TSA because the exposure was limited to 24 h. Thus, although
TSA is now widely established as a potent inhibitor of histone
deacetylases in vitro, metabolically stable inhibitors may be
required to obtain useful activities in vivo.
Acetylation of histone H4 was found to be induced by ABHA
and AAHA, presumably by inhibition of histone deacetylase
activity as shown previously for this class (Richon et al, 1998) and
for TSA (Wolffe and Pruss, 1996). This could be expected to
profoundly alter gene expression and may be a necessary condi-
tion for cell toxicity to occur. However, the present comparison of
acetylation and deacetylation rates in intact sensitive and resistant
cells failed to find any evidence that differences in H4 acetylation
could be responsible for differential toxicity. It is possible that
other histone modifications may be involved in selectivity, or that
other drug targets are important. It should also be noted that some
of the changes in gene expression induced by this type of agent,
presumably by histone hyperacetylation, may be remote from the
origin of toxicity and selectivity. Protein tyrosine phosphatase
activity is involved in regulating cell survival and differentiation
(Stoker and Dutta, 1998) and was required for ABHA to differen-
tiate HeLa cells. This may provide a focus for identifying
signalling pathways relevant to the selective action of ABHA.
The dominant-negative sensitivity to ABHA of somatic cell
hybrids contrasts with the more usual complementation towards
resistance found with other agents such as cisplatin (Wang et al,
1996), and in this study with a DNA methylating agent. It could be
speculated that ABHA sensitivity involves a dominant, mutated
sequence vital to the growth of the transformed phenotype. Loss of
this gene or further mutation under ABHA selection pressure
would lead to non-viable clones. The similar, dominant-negative
phenotype of hybrids from the ABHA-resistant A2058 cells
suggests that malignant transformation may not always be accom-
panied by such changes. The results also show that functional
complementation would not be an appropriate method for cloning
the gene(s) involved in ABHA sensitivity.
Overall, ABHA and AAHA represent a unique class of histone
deacetylase inhibitors that is selectively toxic to transformed cells,
stable in culture, and unlike the more potent inhibitor TSA, active
against human melanoma cells in vivo with no evidence of adverse
effects on the animal or development of drug resistance. Further
refinement in structure may be needed to increase potency and
hence efficacy in vivo.
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